Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC

This is a retrospective cohort study conducted in Hunan Cancer Hospital. Patients (pts) with mCRC who had received at least the 2nd line treatment were eligible. Propensity score (PS) would be calculated to balance the baseline characteristics of two arms. Overall survival (OS) was set as the primary endpoint. From July 2019 to October 2022, 106 eligible pts in total were enrolled. According to the treatment received, 72 and 34 pts were respectively allocated into FP cohort and TB cohort.

Inclusion criteria

• Has histologically confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded).
• Have progressed from at least 2 lines of standard treatment,including fluoropyrimidines, irinotecan, oxaliplatin, with or without targeted drugs, like bevacizumab and cetuximab (only for RAS wild-type). Regorafenib was permitted but not required for inclusion.
• Has measurable or non-measurable disease as defined by RECIST version 1.1
• Is able to swallow oral tablets.
• Estimated life expectancy ≥12 weeks.
• Eastern Cooperative Oncology Group performance status (ECOG PS) less than 2
• Has adequate organ function.

Exclusion criteria

• Pregnancy, lactating female or possibility of becoming pregnant during the study.
• Has not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy (excluding alopecia, and skin pigmentation).
• Has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control CNS disease.
• Has severe or uncontrolled active acute or chronic infection.
• Known carriers of HIV antibodies.
• Confirmed uncontrolled arterial hypertension or uncontrolled or symptomatic arrhythmia.